Infection and Immunity, April 2000, p. 2024-2033, Vol. 68, No. 4
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Department of Microbiology and Immunology, UCLA School of Medicine,1 and Molecular Biology Institute,2 University of California, Los Angeles, California 90095-1747
Received 7 September 1999/Returned for modification 15 November 1999/Accepted 28 December 1999
| |
ABSTRACT |
|---|
|
|
|---|
Fimbriae are filamentous, cell surface structures which have been
proposed to mediate attachment of Bordetella species to respiratory epithelium. Bordetella bronchiseptica has four
known fimbrial genes: fim2, fim3,
fimX, and fimA. While these genes are unlinked
on the chromosome, their protein products are assembled and secreted by
a single apparatus encoded by the fimBCD locus. The
fimBCD locus is embedded within the fha operon,
whose genes encode another putative adhesin, filamentous hemagglutinin
(FHA). We have constructed a Fim
B. bronchiseptica strain, RB63, by introducing an in-frame deletion extending from fimB through fimD. Western blot
analysis showed that RB63 is unable to synthesize fimbriae but is
unaffected for FHA expression. Using this mutant, we assessed the role
of fimbriae in pathogenesis in vitro and in vivo in natural animal
hosts. Although RB63 was not significantly defective in its ability to adhere to various tissue culture cell lines, including human laryngeal HEp-2 cells, it was considerably altered in its ability to cause respiratory tract infections in rats. The number of
fimBCD bacteria recovered from the rat trachea at 10 days postinoculation was significantly decreased compared to that of
wild-type B. bronchiseptica and was below the limit of
detection at 30 and 60 days postinoculation. The number of bacteria
recovered from the nasal cavity and larynx was not significantly
different between RB63 and the wild-type strain at any time point. The
ability of fimbriae to mediate initial attachment to tracheal tissue
was tested in an intratracheal inoculation assay. Significantly fewer
RB63 than wild-type bacteria were recovered from the tracheas at
24 h after intratracheal inoculation. These results demonstrate
that fimbriae are involved in enhancing the ability of B. bronchiseptica to establish tracheal colonization and are
essential for persistent colonization at this site. Interestingly, anti-Bordetella serum immunoglobulin M (IgM) levels were
significantly lower in animals infected with RB63 than in animals
infected with wild-type B. bronchiseptica at 10 days
postinoculation. Even at 30 days postinoculation, RB63-infected animals
had lower serum anti-Bordetella antibody titers in general.
This disparity in antibody profiles suggests that fimbriae are also
important for the induction of a humoral immune response.
| |
INTRODUCTION |
|---|
|
|
|---|
Specific attachment to host tissues is a crucial event in the initiation of bacterial infections. For many gram-negative bacteria, attachment has been shown to be mediated by filamentous polymeric protein cell surface structures called fimbriae (27). For instance, type IV pili of Neisseria species and Pseudomonas aeruginosa, as well as type I and pyelonephritis-associated P (Pap) pili of Escherichia coli, have been shown to serve as essential adhesins for colonization (for reviews, see references 1, 10, 22, 34, and 39).
Bordetella pertussis and Bordetella bronchiseptica are small, aerobic, gram-negative bacteria that colonize the respiratory mucosa of humans and other mammals, respectively. Bordetella genome sequence data (http://www.sanger.ac.uk) indicate the existence of at least four fimbrial structural genes, and other studies (7, 15, 28, 35) reveal that Bordetella species express fimbriae of at least four serotypes, Fim2, Fim3, FimX, and FimA, which are encoded by the fim2, fim3, fimX, and fimA genes, respectively. These genes are unlinked on the Bordetella chromosome, and their protein products are 57 to 60% identical at the amino acid level (7, 15). Although results from in vitro and in vivo studies with B. pertussis are consistent with the hypothesis that fimbriae contribute to the adherence of Bordetella to respiratory epithelium (32, 33), and Fim2 and Fim3 have been included as components of current acellular pertussis vaccines (21), the precise role of fimbriae in pathogenesis has not been conclusively established. A major obstacle has been the lack of a natural animal model for this strictly human pathogen.
Like nearly all of the known and suspected colonization and virulence
factors expressed by Bordetella, fimbriae are regulated at
the transcriptional level by the products of a two-component signal
transduction system encoded by the bvgAS locus (11, 43, 46-48, 50). In vitro, BvgAS is active at 37°C (nonmodulating or Bvg+ phase conditions) and can be inactivated by growth
at low temperature (22°C) or by the presence of nicotinic acid or
MgSO4 (modulating or Bvg
phase conditions) in
the culture media. In addition to BvgAS-dependent regulation, the
B. pertussis fim2, fim3, and fimX
genes are subject to another form of transcriptional control, called
phase variation, which has been suggested as a mechanism by which the
bacteria escape immune recognition (36, 51).
In B. pertussis and B. bronchiseptica, genes
required for secretion and assembly of fimbriae (fimB,
fimC, and fimD) are located between
fhaB and fhaC, genes required for synthesis and
processing of another putative adhesin, filamentous hemagglutinin (FHA)
(Fig. 1A). fhaB encodes a
367-kDa precursor protein (FhaB) which is processed by the
fhaC gene product to form the mature 220-kDa surface-associated and secreted filamentous molecule, FHA (16, 29). The fimBCD gene cluster and fhaC are
transcribed from the fimB promoter and are translationally
coupled (30). Based on amino acid similarity to the
pap gene products, which are involved in the production of P
pili in E. coli, functions have been proposed for the
fimBCD gene products (24). FimB resembles the
chaperone protein, PapD, which appears to prevent degradation of major
fimbrial subunits in the periplasmic space. FimC resembles the usher
protein, PapC, which is probably involved in transport of fimbrial
subunits across the outer membrane and anchorage of the fimbrial
structure (54). FimD is proposed to constitute the adhesive
tip of the Bordetella pilus (52).
|
In this study, we investigated the role of fimbriae in respiratory pathogenesis in the context of a natural host-pathogen interaction. Using a B. bronchiseptica mutant which is unable to synthesize fimbriae due to a deletion in its fimbrial biogenesis locus, we show that fimbriae are required for efficient establishment and persistent colonization of the trachea. Additionally, we show that fimbriae play an important role in the development of humoral immunity to Bordetella infection.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Bacterial strains, plasmids, and growth media.
Wild-type
B. bronchiseptica strain RB50 was isolated in our lab from a
naturally infected rabbit (12). All mutant B. bronchiseptica strains used in this work are derivatives of RB50.
RB53 contains a 1-bp mutation in bvgS corresponding to the
B. pertussis bvgS-C3 allele, which confers a
Bvg+ phase constitutive phenotype. RB54 contains an
in-frame deletion in bvgS which confers it a
Bvg
phase constitutive phenotype. The mutations in the
bvgAS loci of these strains were constructed by allelic
exchange as described previously (3, 12).
polylinker (26) and
replicates autonomously in B. bronchiseptica.
E. coli was grown in Luria-Bertani broth or on Luria-Bertani
agar (31). B. bronchiseptica strains were grown
in Stainer-Scholte medium or on Bordet-Gengou (BG) agar (Becton
Dickinson Microbiology Systems) (6) containing 7.5%
defibrinated sheep blood (Mission Laboratories). Relevant antibiotics
were used at the following concentrations: streptomycin, 20 µg/ml;
kanamycin, 40 µg/ml; chloramphenicol, 50 µg/ml; ampicillin, 100 µg/ml; and gentamicin, 20 µg/ml.
DNA methods.
Isolation of plasmid and chromosomal DNA,
restriction enzyme digestions, agarose gel electrophoresis, and DNA
ligations were performed by standard methods (38).
Restriction enzymes, calf intestinal alkaline phosphatase, Klenow
fragment, T4 DNA ligase, and Sequenase were from Promega Corp.
(Madison, Wis.), Boehringer Mannheim (Indianapolis, Ind.), New England
Biolabs (Beverly, Mass.), or Bethesda Research Laboratories
(Gaithersburg, Md.) and were used according to the manufacturers'
directions. Plasmid constructions were performed with E. coli DH5
(38).
Cloning and construction of RB63.
B. pertussis fimBCD
sequences were obtained from pUW1006 (40). An 892-bp
KpnI-PstI DNA fragment encompassing the
fimB promoter region and a 1,017-bp
PstI-KpnI DNA fragment containing sequences from
fimB and fimC were cloned into pMTL20 (Fig. 1).
DNA fragments from the resulting plasmids were then regenerated as
EcoRI-HindIII fragments, cloned into the
suicide plasmid pEG7 (2) to create plasmids pSM5 and pSM6,
respectively, and transformed into SM10.
pir. pSM5 and pSM6 were each
mobilized into B. bronchiseptica RB50 by conjugation.
Cointegrates were selected on medium containing streptomycin (since
RB50 is streptomycin resistant) and gentamicin. Chromosomal DNA from
the cointegrates was isolated, digested with BamHI (which
has a unique site on the plasmid), and religated to generate plasmids
pCMA4 and pCMA6 (Fig. 1). In this manner, we cloned flanking regions of
B. bronchiseptica DNA. The clones were verified by
restriction enzyme analysis.
fimBCD strain, a 580-bp
SalI-AspI DNA fragment from pCMA6 containing the
promoter region, translational start site, and signal sequence for
fimB was ligated to a 298-bp PstI-PstI
DNA fragment from pCMA4 containing the transcriptional start and signal
sequence for fhaC and then cloned into our allelic exchange
vector, pEGBR, to generate pCMA10. This plasmid confers sucrose
sensitivity and kanamycin resistance. The junctions of the two ligated
fragments in pCMA10 were sequenced to confirm that the reading frames
of the two fragments were undisturbed. pCMA10 was transformed into
SM10.
pir and mobilized into RB50 by conjugation. Transconjugates
were selected on medium containing streptomycin, to select against
E. coli donors, and kanamycin, to select for B. bronchiseptica recipients. Cells in which a second recombination
event had occurred resulting in excision of the plasmid were selected
on medium containing sucrose.
fimBCD candidates were
screened by Western blot analysis using anti-Fim3 antibody, and the
genotype of RB63 was confirmed by Southern blot analysis (data not shown).
To construct a complementing clone for the fimBCD locus, the
minimal open reading frame of the wild-type fimBCD locus was cloned on pBBR1MCS (chloramphenicol resistant) to create plasmid pCMA11. Complementation of the
fimBCD mutation by pCMA11
confirmed that the genomic mutation conferred the observed lack of
fimbrial expression.
Immunoblot analysis. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed by the method of Laemmli (27a), using denaturing 10 and 4 to 12% linear gradient gels (acrylamide-bisacrylamide, 29:1). B. bronchiseptica whole cell lysates were transferred to Immobilon P polyvinylidene difluoride (PVDF) membranes (Millipore) and reacted with the antibody of choice. Dilutions used for the primary antibodies were as follows: anti-Fim2 and anti-Fim3 rabbit polyclonal antibody (courtesy of Fritz Mooi), 1:3,000; anti-FHA rabbit polyclonal antibody (courtesy of Lederle-Praxis), 1:4,000; and rat sera, 1:2,000. Antigen-antibody complexes were detected with horseradish peroxidase (HRP)-conjugated anti-rabbit immunoglobulin (Ig) or anti-rat Ig antibodies (Amersham) at a 1:5,000 dilution and visualized by an enhanced chemiluminescence technique (Amersham).
Enzyme-linked immunosorbent assay (ELISA). Overnight cultures of B. bronchiseptica whole cells were diluted 1:10 in coating buffer (carbonate-bicarbonate buffer, pH 9.6), and 100 µl of suspension was added to each well of a 96-well microtiter plate. The plates were incubated at 37°C for 2 h in a humidified chamber. The wells were washed with phosphate-buffered saline (PBS) plus 1% Tween 20 (PBS-T); then 150 µl of 5% dry instant milk in PBS-T was added to block unbound sites, and the plates were incubated at 37°C for 1 h. Rat antiserum was used as primary antibody; a 100-µl volume of a 1:10 dilution of each serum was added to the first well of the microtiter plate and twofold serially diluted 11 times. Plates were incubated with the primary antibody at 37°C for 2 h, then washed with PBS-T, and incubated at 37°C for 1 h with 100 µl of secondary antibody. For detection of total serum Ig, HRP-conjugated goat anti-rat antibody (Amersham) was used at a 1:5,000 dilution. For detection of serum IgG and IgM, HRP-conjugated goat anti-rat IgG(H+L) (Pierce) and HRP-conjugated goat anti-rat IgM antibodies (Pierce), respectively, were used at a dilution of 1:2,000. For detection of serum IgG2a and IgG2b, a 1:250 dilution of biotin-conjugated mouse anti-rat IgG2a and anti-rat IgG2b (Pharmingen) was used in conjunction with a 1:4,000 dilution of HRP-conjugated streptavidin (Amersham). Absorbance at 402 nm was plotted against dilution, and titers were expressed as the reciprocal of the serum dilution at the x intercept as extrapolated from the linear part of the curve.
In vitro adhesion assay. HEp-2 human laryngeal epithelial cells (American Type Culture Collection [ATCC]) were grown in minimal essential medium containing 10% fetal calf serum in 25-ml vented culture flasks. Once the cells had reached about 90% confluency, 105 HEp-2 cells were seeded onto coverslips in standard 12-well tissue culture plates and incubated overnight at 37°C. The culture medium was removed and replaced with Stainer-Scholte broth containing various concentrations of bacterial strains to be tested so as to obtain multiplicities of infection (MOIs) of 10, 20, 100, 200, 400, and 500. The plates were spun at 900 rpm for 5 min and then incubated at 37°C for 10 min. The cells were then washed four times with Hanks' balanced salt solution, fixed with methanol, stained with Giemsa stain, and visualized by light microscopy.
Animal experiments. (i) Intranasal inoculations. Female Wistar rats were obtained at 3 to 4 weeks of age from Charles River Laboratories (Wilmington, Mass.). Rats were briefly and lightly anesthetized by aerosolized halothane and inoculated intranasally with 5 µl of approximately 500 CFU of B. bronchiseptica in sterile PBS. Inocula were grown at 37°C in Stainer-Scholte medium and normalized by optical density at 600 nm (OD600). The number of CFU delivered was determined by plating dilutions on BG plates. Preinfection sera were collected from the tails of the rats prior to inoculation. At the designated time points postinoculation, rats were euthanized by halothane inhalation and serum samples were obtained by cardiac puncture. Colonization levels in the respiratory tract were determined by removing 1 cm of the trachea, the entire larynx, and the nasal septum, homogenizing each tissue sample in 200 µl of PBS, and growing dilutions of the homogenized tissue on BG plates for 2 days.
(ii) Intratracheal inoculations. Three- to four-week-old female Wistar rats were anesthetized by injecting them in the biceps femoris muscle with 150 µl of a 4:1 mixture of ketamine and xylosine. A small, deep incision was then made in the platysma, and the sternohyoid and sternomastoid muscles were separated to uncover the trachea. Using a 25-gauge needle, 105 bacteria of each Bordetella strain to be tested were injected as a 20-µl volume directly into the trachea. The incision was then sealed using an autoclip. The number of CFU delivered was determined by plating dilutions of the inoculum on BG plates. Colonization levels were determined as described above.
(iii) Measurement of mucosal IgA. Three- to four-week-old female Wistar rats were inoculated intranasally, as described above, with 500 CFU of wild-type or RB63 bacteria, and infection was monitored for 30 days. Animals were then sacrificed, and the trachea and lungs were removed intact. After bronchioalveolar lavage (BAL) (17) using 8 ml of PBS or nasopharyngeal lavage (4) using 4 ml of PBS, 2 ml of each sample was concentrated 10-fold by lyophilizing the sample and resuspending it in 200 µl of PBS. IgA titers measured by ELISA using either RB50 or RB63 as antigen and a 1:2,000 dilution of HRP-conjugated mouse anti-rat IgA antibody (ICN) for detection yielded titers that were below the level of detection. Therefore, total (versus Bordetella-specific) IgA titers were determined by quantitative Western blot analysis. A 1:375 dilution of BAL and nasal washing samples were blotted onto a PVDF membrane and probed with 1:500 dilution of HRP-conjugated goat anti-rat IgA. The signal detected was compared to a standard curve made using purified rat IgA. Data analysis was performed on a Macintosh computer using the public domain NIH Image program (developed at the National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nih-image/).
| |
RESULTS |
|---|
|
|
|---|
Construction of a Fim
B. bronchiseptica
strain.
Hybridization studies using chromosomal DNA from B. pertussis, B. parapertussis, and B. bronchiseptica, as well as recent data from the
Bordetella genome sequencing project
(http://www.sanger.ac.uk), have shown that fimB and its
flanking sequences are conserved among the three subspecies
(54). Further, DNA sequence analysis of the 3' end of
fimC and all of fimD from B. bronchiseptica revealed that the predicted amino acid sequence of
FimD of B. bronchiseptica differs from that of B. pertussis by only one amino acid (52). We took
advantage of the high degree of sequence similarity between B. pertussis and B. bronchiseptica to clone the
fimBCD locus from the chromosome of wild-type B. bronchiseptica strain RB50 (Fig. 1A and Materials and Methods).
Compared to B. pertussis, B. bronchiseptica contained an additional 1 kb of DNA between the 3' end of
fhaB and the 5' end of fimA. Sequence analysis of
the B. bronchiseptica fimA locus revealed that unlike
B. pertussis, B. bronchiseptica contains an
intact fimA gene capable of encoding a 201-amino-acid polypeptide with a molecular mass of approximately 21 kDa
(7). Our results confirm this observation. A few differences
in the restriction pattern were also observed at and beyond the 3' end of fhaC (Fig. 1A).
strain was designated RB63.
In vitro characterization of RB63.
Fimbrial expression in RB63
was examined by Western immunoblot analysis. Whole cell lysates of
wild-type and mutant B. bronchiseptica strains were
separated by SDS-PAGE on a 10% gel, transferred to a PVDF membrane,
and probed with polyclonal antibody generated against the Fim3 subunit
of B. pertussis. This antibody recognized a cluster of three
bands of molecular masses corresponding to that predicted for the major
fimbrial subunits (21 to 24 kDa) as well as other cross-reacting
polypeptides (Fig. 2). The 21 to 24-kDa
polypeptides were expressed in Bvg+ phase bacteria (RB50
grown under nonmodulating conditions and RB53, a Bvg+
phase-locked strain) but were absent in Bvg
phase
bacteria (RB50 grown in the presence of nicotinic acid and RB54, a
Bvg
phase-locked strain). These bands were also absent in
whole cell lysates of RB63 grown under Bvg+ phase
conditions. A similar result was obtained using polyclonal antibodies
generated against Fim2 of B. pertussis (data not shown), indicating that RB63 does not express mature fimbrial proteins recognized by either of these antibodies.
|
fimBCD
mutation. It is likely that accumulation of unassembled major pilus
subunits signals their degradation in the absence of the FimB chaperone.
To verify that the absence of fimbrial expression in RB63 was due to
deletion of the fimBCD genes, the fimBCD gene
cluster was cloned into plasmid pBBR1MCS (26) to construct
pCMA11, which was then electroporated into RB63 (Fig. 1C). Immunoblot
analysis of B. bronchiseptica whole cell lysates probed with
anti-Fim3 antibody revealed that the cluster of bands migrating at
approximately 21 to 24 kDa that was absent in RB63 reappeared in
the complemented strain, RB63(pCMA11) (Fig. 2). Lack of fimbrial
expression in RB63 was, therefore, due to the deletion of the fimbrial
biogenesis genes.
Since fhaC is required for FHA expression, and since FHA
itself serves as a putative adhesin for Bordetella
attachment, it was important that FHA expression in RB63 was not
disrupted by the
fimBCD mutation. To examine the effect
of the fimBCD deletion on FHA expression, whole cell lysates
of wild-type and mutant B. bronchiseptica strains were
probed with polyclonal antibody generated against FHA from B. pertussis (Fig. 3). A cluster of bands migrating at approximately 220 kDa, the predicted size for FHA,
was detected in lysates of RB50 grown under nonmodulating conditions
and of RB53 but was absent in lysates of RB50 grown under modulating
conditions, a
fhaB strain (RBX9), and RB54. RB63 grown
under Bvg+ phase conditions expressed this cluster of
bands, indicating that FHA expression in RB63 was unaltered. Secretion
of FHA was apparently also unaffected by the
fimBCD
mutation as FHA was detected in the supernatants of RB63 at levels
similar to the wild-type level (data not shown).
|
In vitro adherence by fimbrial mutants.
To explore the
possibility that fimbriae function as adhesins in vitro, we compared
RB63 and wild-type B. bronchiseptica for the ability to
adhere to various tissue culture cell lines, including L2 rat lung
epithelial cells (ATCC CCL 149), J774 mouse macrophages (ATCC TIB 67),
HEp-2 human laryngeal epithelial cells (ATCC CCL 23), Caco-2 human
intestinal epithelial cells (ATCC HTB 37), and Intestine 407 human
intestinal epithelial cells (ATCC CCL 6). Although B. bronchiseptica efficiently bound all of these cell lines in a
Bvg+ phase-dependent manner, a role for fimbriae was not
evident. A representative assay with HEp-2 cells, to which B. pertussis has been reported to bind by a fimbria-dependent
mechanism (49), is shown in Fig.
4. Briefly, wild-type or mutant B. bronchiseptica strains were added to confluent monolayers of HEp-2
cells at various MOIs and the number of attached bacteria per HEp-2
cell after incubation was determined by counting Giemsa-stained
bacteria under a light microscope. As expected, Bvg+ phase
bacteria (RB50 grown under nonmodulating conditions) were able to
adhere to HEp-2 cells whereas Bvg
phase bacteria (RB54)
were not (Fig. 4). The number of RB63 bacteria associated with HEp-2
cells was significantly less than for RB50 when used at an MOI of 100, the same MOI at which van den Berg et al. observed a difference in
Fim+ and Fim
B. pertussis binding
to these cells (49). However, at all other MOIs tested (10 to 500), RB63 and RB50 bound with nearly equal efficiency. For all
other cell lines tested as well, the number of bound RB63 and RB50 was
not significantly different at any MOI. Thus, while we propose that
fimbriae do play a role in adherence to respiratory epithelium in vivo
(see below), they do not appear to mediate adherence to the nonciliated
tissue culture cells used in these assays under the conditions
employed. An FHA
mutant, in contrast, was dramatically
impaired in its ability to bind HEp-2 and other cells at all MOIs
tested (Fig. 4 and data not shown). This result confirms a role for FHA
in mediating adherence to epithelial cells in vitro and also
demonstrates that FHA function was not disrupted by the
fimBCD mutation.
|
Fimbriae are required for efficient and persistent colonization of the trachea in a rat respiratory infection model. To investigate the role of fimbriae in vivo, the ability of RB63 to establish infection and to persist at various sites in the respiratory tract was compared with that of RB50 in a rat model (2). This model is extremely sensitive (50% infectious dose of <20 CFU [13]) and allows the role of bacterial virulence factors to be investigated during the course of natural infection (2). In contrast to murine models, in which large numbers of bacteria (104 to 106 CFU of either B. pertussis or B. bronchiseptica) must be delivered in a large volume (25 to 50 µl) to reproducibly observe colonization of the lower respiratory tract, the rat trachea consistently and reproducibly becomes colonized with B. bronchiseptica within 10 days after inoculation with as few as 100 CFU delivered in a 5-µl droplet to the external nares. Moreover, tracheal colonization persists for the life of the animal, allowing us to investigate mechanisms of persistence as well as of initial establishment of infection.
Groups of Wistar rats were inoculated intranasally with approximately 500 CFU of either RB50 or RB63. Animals were sacrificed 10, 30, and 60 days postinoculation, and levels of B. bronchiseptica adhering to the nasal septum, larynx, and trachea were determined. At each of these time points, the numbers of CFU recovered from the nasal cavities of both wild-type- and RB63-inoculated animals were similar, with a mean colonization level of 104 to 105 (Fig. 5). In contrast, at 10 days postinoculation, while B. bronchiseptica were recovered from the tracheas of all animals infected with RB50, only two of the five animals showed evidence of tracheal colonization by RB63. At 30 days postinoculation, the difference between RB50 and RB63 was even more striking: RB50 was recovered from the tracheas of all infected animals, while RB63 was not detected in the tracheas of any of the animals at this time point. At 60 days postinoculation, B. bronchiseptica was recovered from the tracheas of some of the animals infected with RB50 but not from the tracheas of any of the animals infected with RB63. B. bronchiseptica strains lacking fimbriae were, therefore, defective in the ability to colonize the trachea but relatively unaffected in the ability to colonize the nasal cavity. Results were similar for Lewis rats, an in-bred strain derived from Wistar rats.
|
Fimbriae are required for efficient establishment of tracheal
colonization.
Time course studies of rat respiratory tract
colonization following a small-volume (5-µl) intranasal inoculation
with B. bronchiseptica have shown that the nasal cavity
becomes colonized first, followed by colonization of the trachea
(2, 55). In this experimental model of infection, bacteria
in the nasal cavity apparently serve as a reservoir from which the
trachea is seeded. As such, the tracheal colonization defect displayed
by RB63 could be due to a defect in its ability to progress from the
nasal cavity to the trachea, an inability to attach specifically to
tracheal epithelium, and/or an inability to survive the innate or
induced antibacterial defense mechanisms operative in the trachea. To
address these possibilities, we performed two types of experiments. In
the first, we inoculated rats intranasally with a large volume (50 µl) containing 106 CFU of either wild-type bacteria or
RB63. Previous experiments indicate that approximately 10% of the
initial inoculum reaches the trachea when administered in this manner.
Inoculation by this route, therefore, eliminates the requirement that
bacteria be able to translocate from the nasal cavity to the trachea.
At 24 h postinoculation, 105 to 106
Bvg+ phase bacteria (wild-type strain RB50 grown under
nonmodulating conditions) but not Bvg
phase bacteria
(RB54) were recovered per cm of trachea. For RB63, B. bronchiseptica was recovered from the tracheas of only four of the
six animals inoculated by this route, and the number of bacteria
recovered from those animals was significantly decreased compared to
RB50 (103 versus 105 to 106;
P < 0.05) (Fig. 6A).
|
bacteria was less pronounced than in unanesthetized animals. The fact
that Fim
bacteria were defective compared with the wild
type in this assay, however, suggests a role for fimbriae even in a
compromised host. This could reflect a role for fimbriae to enhance
efficiency of adherence to tracheal epithelium, a role that is
partially overcome when bacteria are delivered directly to the trachea
by intratracheal inoculation or when the host defense mechanisms are
overcome by anesthesia.
Taken together, the above results indicate that at least one role for
fimbriae during infection is to enhance the efficiency of B. bronchiseptica to colonize the tracheal epithelium.
Role of fimbriae in development of a humoral immune response.
Rabbits and rats infected with wild-type B. bronchiseptica
generate a strong antibody response directed against numerous
Bvg+ phase factors as well as polypeptides not regulated by
Bvg (2, 12). To investigate the role of fimbriae in the
development of anti-Bordetella humoral immunity, we
quantified anti-Bordetella antibody levels in sera from rats
infected with RB50 or RB63 by ELISA using RB50 whole cells as the
antigen (Fig. 7A). For these experiments
we used Lewis rats, an in-bred strain of Wistar rats, to minimize
animal to animal variations. As mentioned earlier, colonization of
Lewis rats by RB50 and RB63 was similar to that of Wistar rats.
RB50-infected Lewis rats had higher total anti-Bordetella serum antibody levels than RB63-infected rats, and this difference was
significant at 30 days postinoculation. Analysis of specific antibody
isotypes revealed that although IgG levels were higher in RB50-infected
rats than in RB63-infected rats, especially at 10 days postinoculation,
differences in IgM levels were even more dramatic: RB50-infected rats
generated significantly higher anti-Bordetella serum IgM
titers than RB63- infected rats at 10 days postinoculation. By 30 days
postinoculation, the difference in IgM titers between RB50- and
RB63-infected animals was much less apparent. It is likely that most of
the early IgM response had undergone isotype switching by day 30. It
must be noted that since the individual ELISAs use different secondary
and sometimes tertiary antibodies, comparisons between antibody titers
generated in wild-type- and RB63-infected animals can be made only
within one class of antibody (i.e., IgM titers cannot be directly
compared with IgG or total Ig titers, and the sum of IgG plus IgM
titers cannot be expected to equal total Ig titers).
|
B. bronchiseptica bacteria
could not colonize the rat trachea, they induced a serum IgM response
that is similar to that induced by wild-type B. bronchiseptica (reference 14 and data not
shown), indicating that lack of tracheal colonization does not a priori result in a decreased IgM response. The decreased serum IgM response in
RB63-infected rats, therefore, appears to be directly related to the
lack of fimbrial antigens.
Since the generation of IgG isotypes can reflect whether a response is
primarily Th1 or Th2 mediated, we measured
relative anti-Bordetella IgG isotype levels in sera from
RB50- and RB63-infected animals. Quantitative Western blot analysis as
well as ELISAs using wild-type whole cells as antigen were used to
determine IgG2a and IgG2b titers. Similar levels of IgG2b titers were
induced in both wild-type- and RB63-infected Lewis rats (Fig.
8). However, IgG2a titers generated in
wild-type-infected animals were significantly higher than those
generated in RB63-infected animals (Fig. 8). These results suggest that
fimbriae specifically enhance the induction of IgG2a antibodies.
|
| |
DISCUSSION |
|---|
|
|
|---|
The existence of several unlinked fimbrial genes on the
Bordetella chromosome and the lack of a relevant animal
model of infection for B. pertussis have impeded progress in
understanding the role of fimbriae in Bordetella respiratory
infection. In an attempt to overcome these obstacles, we created a
B. bronchiseptica Fim
strain by deleting the
fimBCD biogenesis operon and assessed its pathogenicity in a
rat model of respiratory infection. As natural hosts for B. bronchiseptica, rats provide a sensitive model for investigating
virulence gene function (2). In contrast to wild-type
B. bronchiseptica, fimBCD mutant bacteria
colonized the trachea only sporadically at early time points and were
not recovered from the trachea at or beyond 30 days postinoculation. At
each of these time points, however, the fimbrial mutant was able to
persist in the nasal cavity at levels similar to wild-type levels.
These results confirm and extend previous studies in which it was shown
that Fim
B. pertussis strains were defective
in tracheal colonization in mice (18, 32). That B. bronchiseptica fimbriae, like B. pertussis fimbriae,
contribute to tracheal colonization is further supported by the
observation that Fim
bacteria showed a decreased level of
tracheal colonization even in anesthetized animals. When a large-volume
inoculation of Fim
bacteria was injected directly into
the trachea, the Fim
mutant was recovered from the
trachea at levels significantly lower than the wild-type level.
Together these data demonstrate that fimbriae play an important role in
initial establishment of colonization and an essential role in
long-term persistence in the trachea.
A role for fimbriae in adherence to epithelial cells was not, however,
reflected in our in vitro analyses using various tissue culture cell
lines: the binding efficiencies of wild-type and Fim
B. bronchiseptica strains did not differ over a large range
of MOIs in any of the cell lines tested, including HEp-2 cells.
Although van den Berg et al. reported a role for B. pertussis fimbriae in binding to HEp-2 cells (49), the
conditions of their assay differed significantly from ours and the
number of wild-type B. pertussis cells binding to HEp-2
cells (~0.5 bacterium/cell) in their assay was much lower than the
number of wild-type B. bronchiseptica (Fig. 4) or B. pertussis (data not shown) binding to HEp-2 cells in our assay
(~50 bacteria/cell) when used at the same MOI of 100. Because a
difference in binding specificity for B. pertussis versus
B. bronchiseptica fimbriae could have important implications with regard to host range specificity, we are currently constructing Fim
B. pertussis strains to determine if
B. pertussis fimbriae affect HEp-2 cell binding in our assay
and to establish a basis for comparative analyses.
An interesting effect of fimbrial expression elucidated from this study
was their role in the induction of a serum antibody response. Lack of
fimbriae resulted in decreased induction of Bordetella-specific IgM antibodies. The fact that the high
levels of anti-Bordetella IgM antibodies in sera from
RB50-infected animals were detected in ELISAs using RB50 as the antigen
but not in ELISAs using RB63 (Fim
) as the antigen
suggests that the majority of these antibodies were directed against
fimbriae. The fact that an FHA
strain, which is also
defective in tracheal colonization, induces an IgM response that is not
different from that induced by wild-type B. bronchiseptica
suggests that the decreased IgM response seen in animals infected with
the Fim
strain is a reflection of fimbrial antigenicity
rather than lack of tracheal colonization. B cells can be induced to
secrete IgM in response to binding large polymeric antigens. Our
results suggest that, perhaps due to their polymeric nature, B. bronchiseptica fimbriae may serve as T-independent antigens that
are important for the induction of an early host IgM response.
The specific IgG subtype induced can reflect whether the host immune response is primarily antibody mediated or cell mediated. In rats, IgG1 and IgG2a are considered to be controlled by Th2 cytokines whereas IgG2b and IgG2c are controlled by Th1 cytokines (5, 8, 19). Our analysis showed that while fimbrial mutants were defective in inducing a strong IgG2a response, their ability to induce IgG2b titers was indistinguishable from that of the wild type. However, compared to mock-infected animals, both wild-type- and RB63-infected animals showed an upregulation of both IgG2a and IgG2b titers. These observations suggest that while Bordetella infection induces both Th1 and Th2 responses in the host, fimbriae are important for inducing an immune response that is predominantly Th2 mediated.
Mucosal immune responses form an important defense against respiratory pathogens. Fimbriae have been implicated as important inducers of mucosal responses (23, 45). While Gueirard et al. have reported detection of low levels of IgA in BALB/c mice infected with B. bronchiseptica (20), Bordetella-specific IgA could not be detected in any of the wild-type- or RB63-infected rats in our study. Although consistent with previous studies using B. bronchiseptica in rabbits (12), this result was somewhat surprising. Recent data from our lab suggests that the inability of B. bronchiseptica to induce a mucosal IgA response may be due to the action of toxins secreted by the recently discovered type III secretion system in Bordetella (57). Sera from mice infected with type III-deficient B. bronchiseptica contained high titers of anti-Bordetella IgA, while anti-Bordetella IgA was nearly undetectable in sera from mice infected with wild-type B. bronchiseptica (56). We are currently exploring potential synergystic and/or antagonistic effects of fimbriae and type III secretion in modulation of host immune responses.
Our results suggest two roles for fimbriae: as adhesins enhancing
attachment of Bordetella to respiratory epithelium in the trachea, and as immunomodulators influencing the development of the
humoral immune response to Bordetella infection. Are these two functions related? If recognition of pilus-mediated attachment by
the host is subject to different levels of sensitivity based on the
particular niche in the respiratory tract that becomes colonized, then
the answer may be yes. If so, the niches distinguished by fimbriae must
be present in the nasopharynx, since FHA
bacteria, which
are also defective specifically in tracheal colonization (14), induce a serum antibody response that is qualitatively indistinguishable from that induced by wild-type B. bronchiseptica. This hypothesis suggests that fimbriae may mediate
attachment to specific cell types within the nasopharynx that influence
the subsequent humoral immune response that develops. Alternatively, Fim+ and Fim
bacteria may adhere to the same
population of cells, but fimbriae may mediate binding to a specific
receptor(s) involved in controlling the cytokine pattern induced and
hence the characteristics of the immune response that ultimately
develops. To investigate these hypotheses, we are currently developing
in vivo and ex vivo approaches to identify specific cells in the
respiratory tract to which Bordetella bind, the specific
receptor(s) involved, and the cytokine responses that result.
It is important to recognize, however, that although our data support
the hypothesis that Bordetella fimbriae mediate adherence to
tracheal epithelium and, like others, we are tempted to propose that
they do indeed function as epithelial cell adhesins, this role has not
yet been definitively proven. Lack of efficient establishment and
persistence of tracheal colonization by Fim
bacteria
could result solely from altered interactions between B. bronchiseptica and components of the host's innate or adaptive immune systems. We are hopeful that the development of relevant respiratory tissue models will allow us to definitively determine the
exact functions of these important structures in Bordetella pathogenesis.
| |
ACKNOWLEDGMENTS |
|---|
We thank members of our laboratory for helpful discussions and comments on the manuscript, and we thank F. R. Mooi and Lederle-Praxis for antibodies.
We are supported by grants from NIH (AI43986 to P.A.C. and AI38417 to J.F.M.) and a research training grant from the American Lung Association of California to S.M.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Microbiology and Immunology, UCLA School of Medicine, Center for the Health Sciences, 10833 LeConte Ave., Los Angeles, CA 90095-1747. Phone: (310) 206-0319. Fax: (310) 206-3865. E-mail: pcotter{at}ucla.edu.
Editor: D. L. Burns
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Abraham, S. N., A. B. Jonsson, and S. Normark. 1998. Fimbriae-mediated host-pathogen cross-talk. Curr. Opin. Microbiol. 1:75-81[CrossRef][Medline]. |
| 2. | Akerley, B. J., P. A. Cotter, and J. F. Miller. 1995. Ectopic expression of the flagellar regulon alters development of the Bordetella-host interaction. Cell 80:611-620[CrossRef][Medline]. |
| 3. |
Akerley, B. J.,
D. M. Monack,
S. Falkow, and J. F. Miller.
1992.
The bvgAS locus negatively controls motility and synthesis of flagella in Bordetella bronchiseptica.
J. Bacteriol.
174:980-990 |
| 4. | Asakura, K., H. Saito, M. Hata, and A. Kataura. 1996. Antigen specific immunoglobulin production by NALT lymphocytes in rats. Acta Oto-Laryngol. Suppl. 523:80-83[Medline]. |
| 5. | Binder, J., E. Graser, W. W. Hancock, B. Wasowska, M. H. Sayegh, H. D. Volk, and J. W. Kupiec-Weglinski. 1995. Downregulation of intragraft IFN-gamma expression correlates with increased IgG1 alloantibody response following intrathymic immunomodulation of sensitized rat recipients. Transplantation 60:1516-1524[Medline]. |
| 6. | Bordet, J., and O. Gengou. 1909. L'endotoxine coquelucheuse. Ann. Inst. Pasteur 23:415-419. |
| 7. |
Boschwitz, J. S.,
H. G. J. van der Heide,
F. R. Mooi, and D. A. Relman.
1997.
Bordetella bronchiseptica expresses the fimbrial structural subunit gene fimA.
J. Bacteriol.
179:7882-7885 |
| 8. |
Cetre, C.,
C. Pierrot,
C. Cocude,
S. Lafitte,
A. Capron,
M. Capron, and J. Khalife.
1999.
Profiles of Th1 and Th2 cytokines after primary and secondary infection by Schistosoma mansoni in the semipermissive rat host.
Infect. Immun.
67:2713-2719 |
| 9. | Chambers, S. P., S. E. Prior, D. A. Barstow, and N. P. Minton. 1988. The pMTL nic- cloning vectors. I. Improved pUC polylinker regions to facilitate the use of sonicated DNA for nucleotide sequencing. Gene 68:139-149[CrossRef][Medline]. |
| 10. | Connell, H., M. Hedlund, W. Agace, and C. Svanborg. 1997. Bacterial attachment to uro-epithelial cells: mechanisms and consequences. Adv. Dent. Res. 11:50-58[Abstract]. |
| 11. | Cotter, P. A., and J. F. Miller. 1995. BvgAS dependent phenotypic modulation of Bordetella species, p. 21-42. In R. Rappuoli, V. Scarlato, and B. Arico (ed.), Signal transduction and bacterial virulence. R. G. Landes, Austin, Tex. |
| 12. |
Cotter, P. A., and J. F. Miller.
1994.
BvgAS-mediated signal transduction: analysis of phase-locked regulatory mutants of Bordetella bronchiseptica in a rabbit model.
Infect. Immun.
62:3381-3390 |
| 13. | Cotter, P. A., and J. F. Miller. 1996. Genetic analysis of the Bordetella-host interaction. Ann. N. Y. Acad. Sci. 797:65-76[CrossRef][Medline]. |
| 14. |
Cotter, P. A.,
M. H. Yuk,
S. Mattoo,
B. J. Akerley,
J. Boschwitz,
D. A. Relman, and J. F. Miller.
1998.
Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization.
Infect. Immun.
66:5921-5929 |
| 15. |
Cuzzoni, A.,
P. Pedroni,
B. Riboli,
G. Grandi, and F. de Ferra.
1990.
Nucleotide sequence of the fim3 gene from Bordetella pertussis and homology to fim2 and fimX gene products.
Nucleic Acids Res.
18:1640 |
| 16. | Domenighini, M., D. Relman, C. Capiau, S. Falkow, A. Prugnola, V. Scarlato, and R. Rappuoli. 1990. Genetic characterization of Bordetella pertussis filamentous haemagglutinin: a protein processed from an unusually large precursor. Mol. Microbiol. 4:787-800[CrossRef][Medline]. |
| 17. | Ganz, T., M. P. Sherman, M. E. Selsted, and R. I. Lehrer. 1985. Newborn rabbit alveolar macrophages are deficient in two microbicidal cationic peptides, MCP-1 and MCP-2. Am. Rev. Respir. Dis. 132:901-904[Medline]. |
| 18. | Geuijen, C. A., R. J. Willems, M. Bongaerts, J. Top, H. Gielen, and F. R. Mooi. 1997. Role of the Bordetella pertussis minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract. Infect. Immun. 65:4222-4228[Abstract]. |
| 19. | Gracie, J. A., and J. A. Bradley. 1996. Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass. Eur. J. Immunol. 26:1217-1221[Medline]. |
| 20. | Gueirard, P., P. Minoprio, and N. Guiso. 1996. Intranasal inoculation of Bordetella bronchiseptica in mice induces long-lasting antibody and T-cell mediated immune responses. Scand. J. Immunol. 43:181-192[CrossRef][Medline]. |
| 21. |
Gustafsson, L.,
H. O. Hallander,
P. Olin,
E. Reizenstein, and J. Storsaeter.
1996.
A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
N. Engl. J. Med.
334:349-355 |
| 22. |
Hahn, H. P.
1997.
The type-4 pilus is the major virulence-associated adhesin of Pseudomonas aeruginosa a review.
Gene
192:99-108[CrossRef][Medline].
|
| 23. |
Hedlund, M.,
M. Svensson,
A. Nilsson,
R. D. Duan, and C. Svanborg.
1996.
Role of the ceramide-signaling pathway in cytokine responses to P-fimbriated Escherichia coli.
J. Exp. Med.
183:1037-1044 |
| 24. | Hultgren, S. J., S. Abraham, M. Caparon, P. Falk, J. W. de St. Geme, and S. Normark. 1993. Pilus and nonpilus bacterial adhesins: assembly and function in cell recognition. Cell 73:887-901[CrossRef][Medline]. |
| 25. | Konrad, F., T. Marx, M. Schrag, and J. Kilian. 1997. Combination anesthesia and bronchial transport velocity. Effects of anesthesia with isoflurane, fentanyl, vecuronium, and oxygen-nitrous oxide breathing on bronchial mucus transport. Anaesthesist 46:403-407[CrossRef][Medline]. |
| 26. | Kovach, M. E., R. W. Phillips, P. H. Elzer, R. M. Roop II, and K. M. Peterson. 1994. pBBR1MCS: a broad-host-range cloning vector. BioTechniques 16:800-802[Medline]. |
| 27. | Kuehn, M. J. 1997. Establishing communication via Gram-negative bacterial pili. Trends Microbiol. 5:130-132[CrossRef][Medline]. |
| 27a. | Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227:680-685[CrossRef][Medline]. |
| 28. | Livey, I., C. J. Duggleby, and A. Robinson. 1987. Cloning and nucleotide sequence analysis of the serotype 2 fimbrial subunit gene of Bordetella pertussis. Mol. Microbiol. 1:203-209[CrossRef][Medline]. |
| 29. | Locht, C., P. Bertin, F. D. Menozzi, and G. Renauld. 1993. The filamentous haemagglutinin, a multifaceted adhesion produced by virulent Bordetella spp. Mol. Microbiol. 9:653-660[CrossRef][Medline]. |
| 30. | Locht, C., M. C. Geoffroy, and G. Renauld. 1992. Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families. EMBO J. 11:3175-3183[Medline]. |
| 31. | Maniatis, T., and H. Weintraub. 1992. Gene expression and differentiation [editorial]. Curr. Opin. Genet. Dev. 2:197-198[CrossRef][Medline]. |
| 32. | Mooi, F. R., W. H. Jansen, H. Brunings, H. Gielen, H. G. van der Heide, H. C. Walvoort, and P. A. Guinee. 1992. Construction and analysis of Bordetella pertussis mutants defective in the production of fimbriae. Microb. Pathog. 12:127-135[CrossRef][Medline]. |
| 33. |
Musser, J. M.,
E. L. Hewlett,
M. S. Peppler, and R. K. Selander.
1986.
Genetic diversity and relationships in populations of Bordetella spp.
J. Bacteriol.
166:230-237 |
| 34. | Nassif, X., M. Marceau, C. Pujol, B. Pron, J. L. Beretti, and M. K. Taha. 1997. Type-4 pili and meningococcal adhesiveness. Gene 192:149-53[CrossRef][Medline]. |
| 35. | Pedroni, P., B. Riboli, F. de Ferra, G. Grandi, S. Toma, B. Arico, and R. Rappuoli. 1988. Cloning of a novel pilin-like gene from Bordetella pertussis: homology to the fim2 gene. Mol. Microbiol. 2:539-543[CrossRef][Medline]. |
| 36. | Preston, N. W., R. M. Timewell, and E. J. Carter. 1980. Experimental pertussis infection in the rabbit: similarities with infection in primates. J. Infect. 2:227-235[CrossRef][Medline]. |
| 37. | Ried, J. L., and A. Collmer. 1987. An nptI-sacB-sacR cartridge for constructing directed, unmarked mutations in Gram-negative bacteria by marker exchange-eviction mutagenesis. Gene 57:239-246[CrossRef][Medline]. |
| 38. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 39. |
Soto, G. E., and S. J. Hultgren.
1999.
Bacterial adhesins: common themes and variations in architecture and assembly.
J. Bacteriol.
181:1059-1071 |
| 40. |
Stibitz, S.,
A. A. Weiss, and S. Falkow.
1988.
Genetic analysis of a region of the Bordetella pertussis chromosome encoding filamentous hemagglutinin and the pleiotropic regulatory locus vir.
J. Bacteriol.
170:2904-2913 |
| 41. | Stibitz, S., and M. S. Yang. 1991. Genetic and immunological studies on polypeptides encoded by the vir locus of Bordetella pertussis. Dev. Biol. Stand. 73:87-91[Medline]. |
| 42. |
Stibitz, S., and M. S. Yang.
1991.
Subcellular localization and immunological detection of proteins encoded by the vir locus of Bordetella pertussis.
J. Bacteriol.
173:4288-4296 |
| 43. | Stock, J. B., M. G. Surette, M. G. Levit, and P. Park. 1995. Two-component signal transduction systems: structure-function relationships and mechanisms of catalysis, p. 25-51. In J. Hoch, and T. Silhavy (ed.), Two-component signal transduction. American Society for Microbiology, Washington, D.C. |
| 44. |
Stormo, G. D.,
T. D. Schneider, and L. M. Gold.
1982.
Characterization of translational initiation sites in E. coli.
Nucleic Acids Res.
10:2971-2996 |
| 45. | Svanborg, C., M. Hedlund, H. Connell, W. Agace, R. D. Duan, A. Nilsson, and B. Wullt. 1996. Bacterial adherence and mucosal cytokine responses. Receptors and transmembrane signaling. Ann. N.Y. Acad. Sci. 797:177-190[Abstract]. |
| 46. | Uhl, M. A., and J. F. Miller. 1995. The Bordetella BvgAS signal transduction system, p. 333-349. In T. Silhavy, and J. A. Hoch (ed.), Signal transducing genetic switches. ASM Press, Washington, D.C. |
| 47. |
Uhl, M. A., and J. F. Miller.
1996.
Central role of the BvgS receiver as a phosphorylated intermediate in a complex two-component phosphorelay.
J. Biol. Chem.
271:33176-33180 |
| 48. | Uhl, M. A., and J. F. Miller. 1996. Integration of multiple domains in a two-component sensor protein: the Bordetella pertussis BvgAS phosphorelay. EMBO J. 15:1028-1036[Medline]. |
| 49. |
van den Berg, B. M.,
H. Beekhuizen,
R. J. Willems,
F. R. Mooi, and R. van Furth.
1999.
Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract.
Infect. Immun.
67:1056-1062 |
| 50. | Weiss, A. A., and E. L. Hewlett. 1986. Virulence factors of Bordetella pertussis. Annu. Rev. Microbiol. 40:661-686[CrossRef][Medline]. |
| 51. | Willems, R., A. Paul, H. G. van der Heide, A. R. ter Avest, and F. R. Mooi. 1990. Fimbrial phase variation in Bordetella pertussis: a novel mechanism for transcriptional regulation. EMBO J. 9:2803-2809[Medline]. |
| 52. | Willems, R. J., C. Geuijen, H. G. van der Heide, M. Matheson, A. Robinson, L. F. Versluis, R. Ebberink, J. Theelen, and F. R. Mooi. 1993. Isolation of a putative fimbrial adhesin from Bordetella pertussis and the identification of its gene. Mol. Microbiol. 9:623-634[CrossRef][Medline]. |
| 53. | Willems, R. J., C. Geuijen, H. G. van der Heide, G. Renauld, P. Bertin, W. M. van den Akker, C. Locht, and F. R. Mooi. 1994. Mutational analysis of the Bordetella pertussis fim/fha gene cluster: identification of a gene with sequence similarities to haemolysin accessory genes involved in export of FHA. Mol. Microbiol. 11:337-347[Medline]. |
| 54. | Willems, R. J., H. G. van der Heide, and F. R. Mooi. 1992. Characterization of a Bordetella pertussis fimbrial gene cluster which is located directly downstream of the filamentous haemagglutinin gene. Mol. Microbiol. 6:2661-2671[CrossRef][Medline]. |
| 55. | Yoda, H., K. Nakayama, and M. Nakagawa. 1982. Experimental infection of Bordetella bronchiseptica to rabbits. Jikken Dobutsu 31:113-118[Medline]. |
| 56. | Yuk, M. H., E. T. Harvill, P. A. Cotter, and J. F. Miller. Disruption of type III secretion in Bordetella bronchiseptica leads to increased clearance from the tracheas of immunocompetent mice but increased virulence in immunodeficient mice. Mol. Microbiol., in press. |
| 57. | Yuk, M. H., E. T. Harvill, and J. F. Miller. 1998. The BvgAS virulence control system regulates type III secretion in Bordetella bronchiseptica. Mol. Microbiol. 28:945-959[CrossRef][Medline]. |